Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK jabs deal to 'future-proof' immunisation

12/03/2021 | 01:21am EST

THE GOVERNMENT cut a deal with vaccine makers for millions of new jabs, as Pfizer's boss predicts that booster jabs are here to stay.

The deal for 114m Pfizer-BioNTech and Moderna jabs has secured doses for next year and 2023.

It seeks to "future proof" the UK's immunisation programme, health secretary Sajid Javid said in a statement yesterday.

With new variants of Covid-19 expected to keep emerging as long as there is room for the virus to spread, Pfizer boss Albert Bourla said annual vaccinations will be needed to maintain a "very high level of protection".

The latest strain of the virus, Omicron, had prompted the Government's deal for an undisclosed sum.

However, the World Health Organisation's (WHO) Covid-19 technical lead Maria Van Kerkhove has assured that early signs signal that a number of Omicron cases are "mild".

The Government has snagged around 54m Pfizer jabs and 60m of the Moderna vaccine.

The health secretary added: "This is a national mission and our best weapon to deal with this virus and its variants is to get jabs in arms - so when you are called forward, get the jab and get boosted."

It comes as the WHO looks to launch a global pact on preventing and controlling future pandemics.

The pact seeks to improve the hangups the world has had to manoeuvre during the pandemic, such as data sharing, genome sequencing of emerging variants, and vaccines.

The global health body intends to launch negotiations soon, with the deal expected to be ready by May 2024 and the first stage of talks to be held by the beginning of March next year.

"That may seem like a long process, and it is, but we should not be naive in thinking that reaching a global accord on pandemics will be easy," WHO director-general Tedros Adhanom Ghebreyesus said on Wednesday.

Ghebreyesus added that the number of countries recording Omicron cases is expected to grow - which is likely to have played a role in the Government's acquisition of more vaccines.

"This is what viruses do and what this virus will continue to do as long as we allow it to continue spreading," the WHO director explained.

(c) 2021 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -2.59% 204.73 Delayed Quote.-19.39%
PFIZER, INC. -1.06% 54.95 Delayed Quote.-6.94%
All news about PFIZER, INC.
04:36pGSK And Pfizer Hold Out For 60 Bln Stg Bid For Consumer Health Unit - FT
RE
04:33pGsk and pfizer hold out for ú60bn bid for consumer health unit - ft
RE
07:44aOMICRON-SPECIFIC VACCINE LIKELY TO C : Sharma
AQ
07:23aIndonesia to introduce new tax breaks on property, car sales
RE
01/15GSK rejects $68b Unilever bid for consumer healthcare unit
AQ
01/15Factbox-GSK's consumer health business
RE
01/15GSK rejects 50-billion-pound Unilever offer for consumer assets
RE
01/14U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema
RE
01/14U.S. FDA approves Pfizer's drug to treat eczema
RE
01/14FDA Approves Pfizer's CIBNOQ For Adults With Moderate-to-Severe Atopic Dermatitis
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 916 M - -
Net income 2021 22 210 M - -
Net Debt 2021 27 661 M - -
P/E ratio 2021 14,4x
Yield 2021 2,88%
Capitalization 308 B 308 B -
EV / Sales 2021 4,10x
EV / Sales 2022 3,31x
Nbr of Employees 78 500
Free-Float -
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 54,95 $
Average target price 57,10 $
Spread / Average Target 3,90%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-6.94%308 427
JOHNSON & JOHNSON-1.35%441 855
ROCHE HOLDING AG-3.72%323 901
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444